3.91
-0.02(-0.51%)
Currency In USD
| Previous Close | 3.93 |
| Open | 3.95 |
| Day High | 4.06 |
| Day Low | 3.88 |
| 52-Week High | 11.16 |
| 52-Week Low | 2.9 |
| Volume | 2.49M |
| Average Volume | 3.05M |
| Market Cap | 345.09M |
| PE | -3.23 |
| EPS | -1.21 |
| Moving Average 50 Days | 3.71 |
| Moving Average 200 Days | 5.33 |
| Change | -0.02 |
If you invested $1000 in Altimmune, Inc. (ALT) since IPO date, it would be worth $29.35 as of October 04, 2025 at a share price of $3.91. Whereas If you bought $1000 worth of Altimmune, Inc. (ALT) shares 5 years ago, it would be worth $281.9 as of October 04, 2025 at a share price of $3.91.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide
GlobeNewswire Inc.
Sep 29, 2025 11:30 AM GMT
Seasoned clinical leader to oversee Phase 3 development of pemvidutide in MASH Dr. Arbet-Engels has led late-stage development, regulatory approvals and commercial launches for multiple successful franchises GAITHERSBURG, Md., Sept. 29, 2025 (GLOBE
Altimmune to Participate in Two Upcoming Investor Conferences
GlobeNewswire Inc.
Sep 23, 2025 11:30 AM GMT
GAITHERSBURG, Md., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of
Altimmune Appoints Accomplished Commercial Executive Linda M. Richardson as Chief Commercial Officer
GlobeNewswire Inc.
Sep 15, 2025 11:30 AM GMT
GAITHERSBURG, Md., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced the appointment